Articles
| Open Access |
DOI: Effectiveness Of Domestic Preparation Kromoviz In Treatment Of Allergic Conjunctivites
Nuraliev Nekkadam Abdullaevich , Vice-Rector For Science And Innovation, Bukhara State Medical Institute, Bukhara, Uzbekistan Safarov Jakhongir Oripovich , Assistant Of The Department Of Otorhinolaryngology And Ophthalmology, Bukhara State Medical Institute, Bukhara, Uzbekistan Khasanov Mukhriddin Khayotovich , Assistant Of The Department Of Otorhinolaryngology And Ophthalmology, Bukhara State Medical Institute, Bukhara, UzbekistanAbstract
Purpose: to study the efficacy and tolerability of the domestic drug cromoviz in the treatment of allergic conjunctivitis.
The state of the organ of vision in 60 patients (120 eyes) with allergic conjunctivitis was studied. Depending on the therapy, the patients were divided into two groups of homogeneous clinical manifestations. At the same time, the patients of the main group (30 patients) were instilled with the drug Cromoviz (Uzbekistan), 2 drops 4 times a day for 4 weeks. Patients of the control group (30 patients) were instilled with Aycrol according to the same scheme.
The obtained research results showed that the use of the domestic drug cromoviz against the background of basic treatment is expressed in a decrease in subjective complaints of patients and a significant clinical effect in 95.9% of cases. The revealed economic efficiency of the drug action indicates the achievement of the maximum level of therapeutic result at an acceptable price for the patient and therapeutic-prophylactic institution. Cases of side effects and intolerance to the domestic drug cromoviz were not identified in our studies.
Keywords
Allergic conjunctivitis, mast cell membrane stabilizers, sodium cromoglycate, llergic edema, follicles
References
Bakhritdinova F.A. (2000). Etiopathogenesis, clinical and epidemiological features and treatment of allergic conjunctivitis with pollinosis in Uzbekistan. Moscow: Thought.
Belousova T.A., Goryachkina M.V., Pyatilova P.M. (2015). Antihistamines in clinical practice: optimization of choice from the standpoint of pharmacoeconomics. Medical Review. four: 230.
Brzheskiy V.V. (2017). Some information about the prevalence and modern treatment options for vernal keratoconjunctivitis. Russian Ophthalmological Journal. 4 (10): 74–81.
Brzheskiy V.V. (2018). Allergic conjunctivitis: a guide for an outpatient ophthalmologist.Medical Review. 1 (II):74-9.
Egorov A.E., Zakharova M.A. (2017) .Treatment of a patient with allergic conjunctivitis: recommendations for an outpatient ophthalmologist. Ophthalmology. 2: 111-4.
Kryukov A.I., Ivoilov A.Yu., Pakina (2014). V.R. and other Drug therapy for allergic rhinitis in children. Medical advice. 3: PP. 55-60.
Maychuk, D. Y., & Chilingaryan, L. B. (2012). Tear replacement therapy for allergic eye conditions. Ophthalmology, 2(9), 72-6.
Mirrahimova S. Sh., Narzikulova K. I., Imomalieva K. M. (2018). Clinical manifestations and treatment of allergic conjunctivitis in Uzbekistan. Glaz magazine, Moscow, 5 (123), pp. 42-44.
Neroev V.V., Vakhova E.S. (2018). Allergic conjunctivitis. Ophthalmology: National Guide In the book: S. E. Avetisova, E. A. Egorova, L. K. Moshetova et al. 2nd ed., Revised. and add. Moscow: GEOTAR-Media; 442–56.
Akdis CA, Jutel M., Akdis M. (2008). Regulatory effects of histamine and histamine receptor expression in human allergic immune responses. Chem Immunol Allergy. 94: 67-82.
Mario la rosa, Elena Lionetti,Michele reibaldiet all. (2013). Allergic conjunctivitis: a comprehensive review of the literature. Ital J Pediatr. (39). 18.
O’Brien, T. P. (2013). Allergic conjunctivitis: an update on diagnosis and management. Current opinion in allergy and clinical immunology, 13(5), 543-549.
Ackerman, S., Smith, L. M., & Gomes, P. J. (2016). Ocular itch associated with allergic conjunctivitis: latest evidence and clinical management. Therapeutic advances in chronic disease, 7(1), 52-67.
Stewart, W. C., Stewart, J. A., & Mychaskiw, M. A. (2009). Cost-effectiveness of latanoprost and timolol maleate for the treatment of glaucoma in Scandinavia and the United Kingdom, using a decision-analytic health economic model. Eye, 23(1), 132-140.
Article Statistics
Copyright License
Copyright (c) 2021 The American Journal of Medical Sciences and Pharmaceutical Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.